pocketful logo
Titan Biotech Ltd logo

Titan Biotech Ltd

NSE: BSE: 524717

₹1212.15

(6.53%)

Sat, 14 Feb 2026, 10:26 pm

mtf coin illustrationMTF 5x

Titan Biotech PE Ratio

D/EEVEV/EBITDAP/BP/CFP/EP/SROE %
Particulars200720082009201020112012201320142015201620172018201920202021202220232024
Price to earnings ratio13.9011.9215.9713.288.756.048.1613.8915.3516.4019.1610.564.995.059.996.5517.5616.18
Price to book ratio1.340.991.481.420.790.550.791.111.261.5621.160.902.232.511.483.272.27
Price to sales ratio0.850.630.830.730.480.290.310.560.590.680.850.570.441.081.751.132.662.23
Price to cash flow ratio05.5114.077.198.667.03007.110011.719.328.7310.237.9621.8518.03
Enterprise value109.21M88.68M144.14M160.42M121.53M95.16M171.98M300.25M360.56M550.74M744.39M603.82M596.14M1.67B2.19B1.66B4.42B3.46B
Enterprise value to EBITDA ratio8.286.559.398.365.543.635.397.619.3110.2110.676.764.423.636.925.5412.6413.28
Debt to equity ratio0.070.060.140.290.120.250.460.380.530.981.060.740.610.230.100.080.060.02
Return on equity %08.699.5311.0310.669.2910.019.118.429.7910.7412.2319.8056.2027.9823.8220.4215.01

Titan Biotech Ltd Price to Earnings Ratio

The Titan Biotech Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Titan Biotech Ltd's valuation, profitability, and overall financial performance. Tracking the Titan Biotech Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Titan Biotech Ltd (NSE: , BSE: 524717) is currently trading at ₹1212.15, with a market capitalization of ₹10.02B. As a leading company in the Health technology sector and Biotechnology industry, monitoring the Titan Biotech Ltd Price to Earnings Ratio is essential for fundamental analysis.

Titan Biotech Ltd Price to Earnings Ratio Current Value

The current Titan Biotech Ltd Price to Earnings Ratio stands at 16.18.

The Titan Biotech Ltd Price to Earnings Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.

Titan Biotech Ltd Price to Earnings Ratio Historical Trend

The Titan Biotech Ltd Price to Earnings Ratio has shown the following historical trend:

  • 2024: 16.18
  • 2023: 17.56
  • 2022: 6.55
  • 2021: 9.99
  • 2020: 5.05

The decline in Titan Biotech Ltd Price to Earnings Ratio indicates improving financial efficiency or better earnings growth.

What Titan Biotech Ltd Price to Earnings Ratio Indicates for Investors

The Titan Biotech Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.

A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.

Titan Biotech Ltd Price to Earnings Ratio Analysis Summary

The Titan Biotech Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Titan Biotech Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Titan Biotech Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800